Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/46944
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Flicker, L. | - |
dc.contributor.author | Vasikaran, S. | - |
dc.contributor.author | Thomas, J. | - |
dc.contributor.author | Acres, J. | - |
dc.contributor.author | Norman, P. | - |
dc.contributor.author | Jamrozik, K. | - |
dc.contributor.author | Hankey, G. | - |
dc.contributor.author | Almeida, O. | - |
dc.date.issued | 2006 | - |
dc.identifier.citation | Stroke, 2006; 37(2):547-549 | - |
dc.identifier.issn | 0039-2499 | - |
dc.identifier.issn | 1524-4628 | - |
dc.identifier.uri | http://hdl.handle.net/2440/46944 | - |
dc.description.abstract | Background and Purpose— A higher plasma concentration of total homocysteine (tHcy) is associated with a greater risk of cardiovascular events. Previous studies, largely in younger individuals, have shown that B vitamins lowered tHcy by substantial amounts and that this effect is greater in people with higher tHcy and lower folate levels. Methods— We undertook a 2-year, double-blind, placebo-controlled, randomized trial in 299 men aged 75 years, comparing treatment with a daily tablet containing 2 mg of folate, 25 mg of B6, and 400 µg of B12 or placebo. The study groups were balanced regarding age (mean±SD, 78.9±2.8 years), B vitamins, and tHcy at baseline. Results— Among the 13% with B12 deficiency, the difference in mean changes in treatment and control groups for tHcy was 6.74 µmol/L (95% CI, 3.94 to 9.55 µmol/L) compared with 2.88 µmol/L (95% CI, 0.07 to 5.69 µmol/L) for all others. Among the 20% with hyperhomocysteinaemia, the difference between mean changes in treatment and control groups for men with high plasma tHcy compared with the rest of the group was 2.8 µmol/L (95% CI, 0.6 to 4.9 µmol/L). Baseline vitamin B12, serum folate, and tHcy were significantly associated with changes in plasma tHcy at follow-up (r=0.252, r=0.522, and r=–0.903, respectively; P=0.003, <0.001, and <0.001, respectively) in the vitamin group. Conclusions— The tHcy-lowering effect of B vitamins was maximal in those who had low B12 or high tHcy levels. Community-dwelling older men, who are likely to be deficient in B12 or have hyperhomocysteinemia, may be most likely to benefit from treatment with B vitamins. | - |
dc.description.statementofresponsibility | Leon Flicker, Samuel D. Vasikaran, Jenny Thomas, John M. Acres, Paul Norman, Konrad Jamrozik, Graeme J. Hankey and Osvaldo P. Almeida | - |
dc.language.iso | en | - |
dc.publisher | Lippincott Williams & Wilkins | - |
dc.rights | © 2006 American Heart Association | - |
dc.source.uri | http://stroke.ahajournals.org/cgi/content/abstract/37/2/547 | - |
dc.subject | aged | - |
dc.subject | clinical trial | - |
dc.subject | homocysteine | - |
dc.subject | vitamins | - |
dc.subject | vitamin B12 deficiency | - |
dc.title | Efficacy of B vitamins in lowering homocysteine in older men: Maximal effects for those with B12 deficiency and hyperhomocysteinemia | - |
dc.type | Journal article | - |
dc.identifier.doi | 10.1161/01.STR.0000198815.07315.68 | - |
pubs.publication-status | Published | - |
Appears in Collections: | Aurora harvest 6 Public Health publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.